Literature DB >> 687505

Individual variation in daily dosage requirements for phenytoin sodium in patients with epilepsy.

M H Barot, R H Grant, K K Maheendran, G E Mawer, B G Woodcock.   

Abstract

1 Ninety adult patients receiving phenytoin sodium were studied prospectively in an epileptic centre. Serum concentrations of phenytoin under steady state conditions were measured by gas liquid chromatography. When clinically indicated the daily dosage rate was adjusted by 50 mg steps until a serum concentration of 10--20 mg/l was produced. 2 Concentrations within the above range were obtained in 50 patients; the required dosage rate varied from 200--500 mg/day. Twenty-five clinical, biochemical and haematological attributes were recorded for each patient and tested for correlation with dosage requirement. 3 The dosage requirement correlated most strongly (r = 0.57, P less than 0.001) with body surface area. This relationship (approximately 200 mg/day per m2) accounted however for only one third of the total dosage variance. 4 Amongst 18 patients receiving simultaneous treatment with phenobarbitone, the effective plasma clearance of this drug taken in conjunction with body surface area accounted for a significantly greater proportion of the total dosage variance. Multiple regression analysis failed to reveal other, more widely applicable predictors of individual phenytoin dosage requirements.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 687505      PMCID: PMC1429455          DOI: 10.1111/j.1365-2125.1978.tb04596.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin.

Authors:  F BUCHTHAL; O SVENSMARK; P J SCHILLER
Journal:  Arch Neurol       Date:  1960-06

2.  Rapid evaluation of creatinine clearance.

Authors:  K Siersbaek-Nielsen; J M Hansen; J Kampmann; M Kristensen
Journal:  Lancet       Date:  1971-05-29       Impact factor: 79.321

3.  Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man.

Authors:  J Hunter; J D Maxwell; M Carrella; D A Stewart; R Williams
Journal:  Lancet       Date:  1971-03-20       Impact factor: 79.321

4.  Biochemical studies on glucuronic acid and glucaric acid. 1. Quantitative chemical determination of D-glucaric acid in urine.

Authors:  M Ishidate; M Matsui; M Okada
Journal:  Anal Biochem       Date:  1965-05       Impact factor: 3.365

5.  Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels.

Authors:  A L Sherwin; J S Loynd; G W Bock; C D Sokolowski
Journal:  Epilepsia       Date:  1974-12       Impact factor: 5.864

6.  Rapid determination of diphenylhydantoin in blood plasma by gas-liquid chromatography.

Authors:  J MacGee
Journal:  Anal Chem       Date:  1970-03       Impact factor: 6.986

7.  Serum-phenytoin levels in management of epilepsy.

Authors:  A Richens; A Dunlop
Journal:  Lancet       Date:  1975-08-09       Impact factor: 79.321

8.  The clinical pharmacokinetics of phenytoin.

Authors:  E Martin; T N Tozer; L B Sheiner; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

9.  One drug (phenytoin) in the treatment of epilepsy.

Authors:  E H Reynolds; D Chadwick; A W Galbraith
Journal:  Lancet       Date:  1976-05-01       Impact factor: 79.321

10.  Unnecessary polypharmacy for epilepsy.

Authors:  S D Shorvon; E H Reynolds
Journal:  Br Med J       Date:  1977-06-25
View more
  2 in total

Review 1.  An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of phenytoin.

Authors:  A Richens
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.